Scott Juda insider trades: Inmune Bio (INMB) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Scott reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 25, 2024 | INMB | ↑ Buy | 5,000 | $7.27 | $36K | Indirect | Jun 26, 2024 (1d) |
| Nov 10, 2023 | INMB | ↑ Buy | 7,000 | $6.95 | $49K | Indirect | Nov 13, 2023 (3d) |
| Nov 17, 2021 | INMB | ↑ Buy | 2,500 | $13.55 | $34K | Indirect | Nov 17, 2021 (0d) |
| Aug 21, 2019 | INMB | ↑ Buy | 5,000 | $6.00 | $30K | Direct | Aug 22, 2019 (1d) |
| Jun 3, 2019 | INMB | ↑ Buy | 10,000 | $6.00 | $60K | Direct | Jun 4, 2019 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Scott Juda's insider trades
Scott Juda is a director at Inmune Bio (INMB). Since Jun 3, 2019, Scott has reported 5 open-market purchases worth $209K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (10 filings), option exercises (1 filing), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every INMB insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.